By cotargeting NKp46 and CD16, which led to full NK cell activation, the trifunctional NK cell engagers showed more efficient promotion of NK cell activation and cytotoxicity in vitro and more effective control of tumor growth in mouse models of solid and invasive tumors compared with those of current clinically available therapeutic antibodies. Here, NCR1 is linked to neoplasm.